Loading...

PE anti-mouse NK-1.1 Antibody

Pricing & Availability
Clone
PK136 (See other available formats)
Regulatory Status
RUO
Other Names
NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
PK136_PE_NK-11_Antibody_051018
C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
  • PK136_PE_NK-11_Antibody_051018
    C57BL/6 mouse splenocytes were stained with CD49b (DX5) APC and NK1.1 (clone PK136) PE (left) or mouse IgG2a, κ PE isotype control (right).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
108707 50 µg 61 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108708 200 µg 179 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells in vitro and rejection of bone marrow allografts in vivo. NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
NK-1+ cells from mouse spleen and bone marrow
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, complement-dependent cytotoxicity3, in vivo depletion4,5,9,10, mediation of in vitro redirected lysis6, blocking of NK cell function7, induction of proliferation8, immunohistochemical staining of frozen sections11, immunofluorescence microscopy11, and spatial biology (IBEX)16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References

(PubMed link indicates BioLegend citation)
  1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
  2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
  3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
  4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
  5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
  6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
  8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
  9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
  10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
  11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
  12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
  13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
  14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  2. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  3. Sade-Feldman M,et al. 2017. Nat Commun.. 10.1038/s41467-017-01062-w. PubMed
  4. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  5. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  6. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  8. Israelow B, et al. 2020. bioRxiv. . PubMed
  9. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  10. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  11. Zheng M, et al. 2016. Sci Rep. 6:28729. PubMed
  12. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  13. Valencia–Hernandez AM, et al. 2020. Cell Host & Microbe. 27(6):950-962. PubMed
  14. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  15. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  16. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  17. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  18. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  19. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  20. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  21. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  22. Adomati T, et al. 2020. Cell Reports. 30(11):3671-3681. PubMed
  23. Hsieh M, et al. 2006. J Immunol. 177:1855. PubMed
  24. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  25. Liu X, et al. 2020. Nature. . PubMed
  26. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  27. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  28. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  29. Böttcher JP, et al. 2018. Cell. 172:1022. PubMed
  30. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  31. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  32. Shibata K, et al. 2014. J Immunol. 192:2210. PubMed
  33. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  34. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  35. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  36. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  37. Astrakhan A, et al. 2009. J Immunol. 182:7370. PubMed
  38. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  39. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  40. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  41. Marsh S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1316 - 1325. PubMed
  42. Spees A, et al. 2014. Infect Immun . 82:1692. PubMed
  43. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  44. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  45. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  46. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  47. Li J, et al. 2019. JCI Insight. 5. PubMed
  48. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  49. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  50. Martens CR, et al. 2022. PLoS Pathog. 18:e1010342. PubMed
  51. Zhou Y, et al. 2022. Nat Commun. 13:2906. PubMed
  52. Qiu Z, et al. 2016. Sci Rep. 6:31936. PubMed
  53. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  54. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  55. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  56. Ruf B, et al. 2021. Cancer Immunol Res. 9:1024. PubMed
  57. McAlpine CS, et al. 2021. Nature. 595:701. PubMed
  58. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  59. Hulsmans M et al. 2017. Cell. 169(3):510-522 . PubMed
  60. Galvani E, et al. 2020. Nat Commun. 11:853. PubMed
  61. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  62. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  63. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  64. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  65. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  66. Markman JL, et al. 2020. Nat Commun. 11:1613. PubMed
  67. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  68. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  69. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  70. Kadowaki T, et al. 2012. Clin Immunol. 142:296. PubMed
  71. Olson M, et al. 2014. J Immunol. 193:5420. PubMed
  72. Kim DH, et al. 2018. Nat Commun. 9:503. PubMed
  73. Li Z, et al. 2018. Front Immunol. 9:347. PubMed
  74. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  75. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  76. Duan B, et al. 2010. J Immunol. 185:335. PubMed
  77. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  78. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  79. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  80. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  81. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  82. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  83. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  84. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  85. Bachu M, et al. 2019. J Biol Chem. 294:1904. PubMed
  86. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  87. Lang V, et al. 2021. Elife. 10:. PubMed
  88. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  89. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  90. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  91. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  92. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  93. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  94. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  95. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  96. Gamrekelashvili J, et al. 2021. Bio Protoc. 11:e4007. PubMed
  97. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  98. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  99. Lokken K, et al. 2014. PLoS Pathog. 10:1004049. PubMed
  100. Hohsfield LA, et al. 2020. J Neuroinflammation. 0.902083333. PubMed
  101. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  102. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  103. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  104. Okamoto T, et al. 2011. Biomaterials. 32:4925. PubMed
  105. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  106. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  107. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  108. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  109. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  110. He B, et al. 2020. Cell Reports. 30(3):714-724.e5.. PubMed
  111. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  112. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
  113. Israelow B, et al. 2020. J Exp Med. 217:00:00. PubMed
  114. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  115. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  116. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  117. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  118. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  119. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  120. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  121. Tähtinen S, et al. 2022. Nat Immunol. 23:532. PubMed
  122. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  123. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  124. Orr MT, et al. 2019. NPJ Vaccines. 4:1. PubMed
  125. Sartorius R, et al. 2018. Front Immunol. 1.413888889. PubMed
  126. Zhou X, et al. 2021. Nutr Metab (Lond). 18:64. PubMed
  127. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  128. Dienz O, et al. 2009. J Exp Med. 206:69. PubMed
  129. Wu C, et al. 2018. Scand J Immunol. 87:e12661. PubMed
  130. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
  131. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  132. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
RRID
AB_313394 (BioLegend Cat. No. 108707)
AB_313395 (BioLegend Cat. No. 108708)

Antigen Details

Structure
NKR-P1 gene family
Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function
NK cell activation, IFN-γ production, cytotoxic granule release
Cell Type
NK cells, NKT cells
Biology Area
Immunology, Innate Immunity
Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID
17059 View all products for this Gene ID
UniProt
View information about NK-1.1 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All NK-1.1 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse NK-1.1 PK136 FC
Biotin anti-mouse NK-1.1 PK136 FC
FITC anti-mouse NK-1.1 PK136 FC
PE anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
PE/Cyanine7 anti-mouse NK-1.1 PK136 FC
PE/Cyanine5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 488 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 647 anti-mouse NK-1.1 PK136 FC
Pacific Blue™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 711™ anti-mouse NK-1.1 PK136 FC
APC/Cyanine7 anti-mouse NK-1.1 PK136 FC
PerCP anti-mouse NK-1.1 PK136 FC
PerCP/Cyanine5.5 anti-mouse NK-1.1 PK136 FC
Alexa Fluor® 700 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 421™ anti-mouse NK-1.1 PK136 FC,SB
Brilliant Violet 570™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 650™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 510™ anti-mouse NK-1.1 PK136 FC
Brilliant Violet 605™ anti-mouse NK-1.1 PK136 FC
Purified anti-mouse NK-1.1 (Maxpar® Ready) PK136 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse NK-1.1 PK136 FC
Brilliant Violet 785™ anti-mouse NK-1.1 PK136 FC
APC/Fire™ 750 anti-mouse NK-1.1 PK136 FC
TotalSeq™-A0118 anti-mouse NK-1.1 PK136 PG
Ultra-LEAF™ Purified anti-mouse NK-1.1 PK136 FC,CyTOF®,IP,Depletion,Block,IHC-F
TotalSeq™-B0118 anti-mouse NK-1.1 PK136 PG
TotalSeq™-C0118 anti-mouse NK-1.1 PK136 PG
PE/Fire™ 810 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 640 anti-mouse NK-1.1 PK136 FC
Spark UV™ 387 anti-mouse NK-1.1 PK136 FC
PE/Fire™ 700 anti-mouse NK-1.1 PK136 FC
Go To Top Version: 3    Revision Date: 05.10.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account